Preclinical drug development

Together with a partner (PKI) smv3.ch does consulting in drug development for a small local pharma company. We complete the preclinical portfolio by managing nonclinical and later clinical studies. After a gap analysis by PKI we have developed a proposal for study packages on various analytical, drug metabolism and drug-drug interaction aspects including timelines, cost estimates and suitable CRO partners. Now that the costs have been endorsed we manage the collaborations, evaluate the results and prepare regulatory compliant reports. In our partnership, smv3.ch is responsible for the analytical details, early stages and informatics, PKI for the strategic, cost and regulatory aspects.